Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dyural LM kit is a branded combination pharmaceutical kit marketed by Asclemed USA that contains methylprednisolone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidone iodine, and isopropyl alcohol. It is packaged for use in local or regional anesthesia or analgesia procedures, including surgical, dental, diagnostic, therapeutic, and obstetrical settings. The pharmacologically active anesthetic components, lidocaine and bupivacaine, are small-molecule amide local anesthetics that block voltage-gated sodium channels in peripheral nerves to inhibit initiation and propagation of pain impulses, while methylprednisolone acetate is a corticosteroid included in the kit and povidone iodine and isopropyl alcohol serve antiseptic roles. Based on the provided context, this product is described as an unapproved drug product whose labeling has not been approved by the FDA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dyural LM kit.